Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease
Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease
The purpose of our study is to investigate CSF and blood biomarkers among the subjects with mild cognitive impairment (MCI) and Alzheimer's disease (AD) as well as normal controls.
Alzheimer's disease is the most prevalent cause of dementia. A biomarker is a variable that are measured in vivo and indicate specific features of disease related molecular mechanisms and pathologic changes, including amyloid processing and aggregation, tau hyperphosphorylation, accumulation of neurofibrillary tangles, synaptic dysfunction, neurodegeneration, and loss of brain tissue.
We examine serum oligomeric beta-amyloid 42 and CSF monomeric beta-amyloid 42, total tau and phosphorylated tau, as well as PiB-PET, FDG-PET and brain MRI in 90 participants (30 normal controls, 30 patients with mild cognitive impairment, 30 patients with Alzheimer's disease).
Inclusion Criteria:
Exclusion Criteria:
-
kumimesy@gmail.com82-10-6287-8084
neuroksy@snu.ac.kr82-31-787-7462